DAA-PASS: A Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in HCV-Infected Patients after Direct-Acting Antiviral Therapy First published 01/03/2018 Last updated 23/04/2024 EU PAS number:EUPAS22896 Study Finalised